Podiatry has never been the flashiest corner of medicine. Foot and ankle care tends to fly under the radar – no dramatic surgeries, no headline-grabbing treatments, just a steady, predictable stream of patients with heel pain, diabetic foot complications, ingrown toenails, and sports injuries. That predictability is exactly what makes it attractive to private equity firms hunting for the next specialty to roll up.
Across the country, solo practitioners and small group podiatry practices are receiving acquisition offers – often unsolicited – from PE-backed management services organizations. Some owners are taking the deals. Others are watching their neighbors sell and quietly asking their accountants what their own practices might be worth.
The deals are happening fast, and mostly out of public view.
Why Podiatry, and Why Now
Private equity’s interest in specialty medicine follows a recognizable logic: find a fragmented market with stable demand, acquire practices at scale, centralize administrative functions, then either grow the platform further or sell it to a larger buyer. Podiatry checks every box. There are thousands of independent practices spread across the country, the majority still owned by the founding physician. Consolidation in the specialty remains low compared to fields like dermatology or orthopedics, which means there is still significant arbitrage available to early movers willing to build a national or regional footprint.
The demand side of the equation is equally attractive. An aging population means more diabetic foot disease, peripheral vascular complications, and degenerative joint conditions – all conditions that land patients in a podiatrist’s chair on a recurring basis. Unlike a surgical specialty where each case is episodic, podiatry often generates long-term patient relationships with multiple visits per year. For a PE model built around predictable cash flow, that recurring revenue profile is worth paying a premium for.
Reimbursement stability adds another layer. While many specialties have faced significant cuts from Medicare and commercial payers over the past decade, routine podiatry procedures have largely held their rates. That relative stability, combined with the high proportion of Medicare-eligible patients in the typical podiatry practice, gives acquirers confidence in their financial models.
What the Deals Actually Look Like
Most podiatry acquisitions follow a structure that has become standard across PE-backed healthcare rollups. The selling physician receives an upfront cash payment – typically a multiple of the practice’s EBITDA – and then rolls some equity into the acquiring platform. That equity stake is the hook: if the platform grows and eventually sells at a higher multiple, the original owner theoretically participates in the upside. Physicians who sold early into dermatology or ophthalmology rollups sometimes made significant money on their rolled equity. That narrative travels fast in medical communities.
After the transaction closes, the practice typically enters into a management services agreement with the PE-backed organization. The acquirer takes control of billing, HR, real estate, vendor contracts, and marketing. The physician retains clinical autonomy – at least on paper. In practice, decisions about staffing levels, appointment volume, ancillary service lines, and facility investments tend to migrate toward the management company over time. Physicians who have gone through the process describe a gradual shift in who actually controls day-to-day operations, even when their employment agreements say otherwise.
This pattern is not unique to podiatry. Regional pain management clinics have moved through a nearly identical cycle – early acquisition activity, a period of rapid platform building, and then increased scrutiny from physicians inside those platforms about the gap between promised autonomy and operational reality. Podiatry appears to be about two to three years behind that curve.
The Seller’s Calculation
For a solo podiatrist who built a practice over 20 or 25 years, the appeal of a PE deal is not purely financial. Administrative burden has intensified dramatically over the past decade – prior authorization requirements, EHR compliance, credentialing renewals, MIPS reporting, and staffing shortages that are impossible for a small practice to absorb gracefully. Selling to a well-capitalized platform theoretically offloads all of that onto someone else. The physician keeps seeing patients and collects a salary while the management company handles everything else. To someone who is burned out on running a small business while also practicing medicine, that pitch lands.
The financial terms can be genuinely attractive, particularly for practices that have strong ancillary revenue from custom orthotics, in-office surgical procedures, or wound care programs. A practice generating solid EBITDA can command a meaningful acquisition multiple, and for physicians without a clear succession plan – no associate to buy them out, no family member entering the field – a PE transaction may represent the only realistic path to liquidity. Selling to a competitor practice or bringing on a junior partner both require years of transition work that many late-career physicians simply do not have the energy to manage.
What sellers often underestimate is how much the culture of a practice changes after an acquisition. The podiatrists who sold into early ophthalmology and dermatology rollups frequently describe a version of the same experience: the first year feels largely unchanged, the second year brings new metrics and productivity expectations, and by the third year the practice looks and operates in ways that would have been unrecognizable to its original staff. Patient wait times increase, appointment slots shorten, and ancillary services get pushed more aggressively because they improve platform-level margins. None of that is necessarily dishonest – it is simply the logic of a business optimization model applied to a clinical environment.
Where This Is Headed
The podiatry rollup wave is still early enough that sellers have real negotiating leverage and platforms are competing with each other for quality practices. That window will not stay open indefinitely. Once three or four well-capitalized platforms control a significant share of the market in any given region, the competitive dynamics shift – independent practices face both a thinning patient referral network and a more difficult recruitment environment as employed positions at PE platforms offer guaranteed salaries that private practice can struggle to match. The physicians deciding whether to sell right now are not just making a personal financial choice; they are making a bet on whether their market will look materially different in five years, and whether they want to be inside the consolidating structure or outside of it when that moment arrives.
Frequently Asked Questions
Why are private equity firms buying podiatry practices?
Podiatry offers stable Medicare reimbursement, recurring patient visits, and a highly fragmented ownership landscape – all conditions that make it ideal for PE-style rollup consolidation.
What happens to a podiatry practice after a PE acquisition?
The acquiring firm typically takes over billing, HR, and operations through a management services agreement, while the physician remains employed. Clinical autonomy often narrows over time as productivity metrics and margin targets take priority.
